Abstract
Primary HIV infection is a critical and highly dynamic time period in the course of HIV infection. The initial pathologic processes are important in determining long-term disease progression. In the absence of our ability to eradicate the virus, identifying individuals during primary HIV infection and performing interventions that optimize outcome are important to provide adequate care to a newly infected patient and, from a public health perspective, to identify sexual networks and provide a platform to reduce HIV exposures during a time of high viremia.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Joint United Nations Programme on HIV/AIDS: Table of UNAIDS/WHO global and regional HIV/AIDS estimates end-2002. http://www.unaids.org/html/pub/Topics/Epidemiology/ RegionalEstimates2002_en_pdf.htm. Accessed October 1, 2003. This is a great source for general HIV epidemiologic statistics.
HIV incidence among young men who have sex with men-seven U.S. cities, 1994–2000. MMWR Morb Mortal Wkly Rep 2001, 50:440–444.
Shacker T, Collier AC, Hughes J, et al.: Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996, 125:257–264.
Cooper D, Gold J, Maclean P, et al.: Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985; 1:537–540.
Vanhems P, Dassa C, Lambert J, et al.: Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. J Acquir Immune Defic Syndr 1999, 21:99–106.
Kahn J, Walker BD: Acute human immunodeficiency virus type-1. N Engl J Med 1998, 339:33–40. This is another excellent review of acute HIV infection, emphasizing pathogenesis, diagnosis, and potential treatment.
Hecht FM, Busch MP, Rawal B, et al.: Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002, 16:1119–1129. This large study of patients with primary infection evaluates clinical signs and laboratory tests for diagnosis.
Pedersen C, Lindhardt BO, Jensen BL, et al.: Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989, 299:154–157.
Busch MP, Lee LL, Satten GA, et al.: Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995, 35:91–97.
Fiebig EW, Wright DJ, Rawal BD, et al.: Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871–1879.
Janssen R, Satten G, Stramer S, et al.: New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998, 280:42–48.
Spira AI, Marx PA, Patterson BK, et al.: Cellular targets of infection and route of viral dissemination following an intravaginal inoculation of SIV into rhesus macaques. J Exp Med 1996, 183:215–225.
Clark SJ, Saag MS, Decker WD, et al.: High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991, 324:954–960.
Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993, 261:1179–1181.
Roos M, De Leeuw N, Claessen F, et al.: Viro-immunological studies in acute HIV-1 infection. AIDS 1994, 8:1533–1538.
Musey L, Hughes J, Schacker T, et al.: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267–1274.
Pantaleo G, Demarest JF, Schacker T, et al.: The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997, 94:254–258.
Yang OO, Kalams SA, Trocha A, et al.: Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997, 71:3120–3128.
Roos M, De Leeuw N, Claessen F, et al.: Viro-immunological studies in acute HIV-1 infection. AIDS 1994, 8:1533–1538.
Pilgrim AK, Pantaleo G, Cohen OJ, et al.: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997, 176:924–932.
Mellors JW, Kingsley LA, Rinaldo, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573–579.
Koopman JS, Jacquez JA, Welch GW, et al.: The role of early HIV infection in the spread of HIV through populations. J Acquir Immun Defic Syndr 1994, 7:1169–1184.
Erice A, Mayers DL, Strike DG, et al.: Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:1163–1165.
Hecht FM, Grant RM, Hellman N, et al.: Transmission of human immunodeficiency virus type-1 resistant to multiple reverse transcriptase and protease inhibitors. N Engl J Med 1998, 339:307–311.
Little SJ, Daar ES, D’Aquila RT, et al.: Reduced antiviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142–1149. This is the first large study to evaluate primary drug resistance.
Balotta C, Berlusconi A, Pan A, et al.: Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther 2000, 5:7–14.
UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001, 322:1087–1088.
Boden D, Hurley A, Zhang L, et al.: HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282:1135–1141.
Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385–394. This paper demonstrates the changes in transmitted HIV resistance over time.
Yerly S, Vora S, Rizzardi P, et al.: Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001, 15:2287–2292.
Grant RM, Hecht FM, Warmerdam M, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181–188. This study also shows the changes in primary HIV resistance over time.
Wensing AMJ, van de Vijver DAMC, Asjo B, et al.: Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-study [abstract 117]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Cabos, Mexico: 2003:S131.
Routy JP, Brenner B, Rouleau D, et al.: Drug resistance prevalence declines in recently infected subjects having sex with men but not in those using drug infections: results from the Montreal Primary HIV-Infection Cohort [abstract 122]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S136.
Pillay D, Green H: The UK drug resistance database: development and use for national surveillance [abstract 124].Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S138.
Bennett DE, Zaidi IF, Heneine W, et al.: Prevalence of mutations associated with antiretroviral drug resistance among men and women newly diagnosed with HIV in 10 US cities, 1997–2001 [abstract 119]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S133.
Jayaraman GC, Gleeson T, Sandstrom P, Archibald CP: The Canadian HIV strain and drug resistance program--a population-based effort to enhance HIV surveillance [abstract 121]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S135.
Grant RM, Liegler T, Spotts G, Hecht FM: Declining nucleoside reverse transcriptase inhibitor primary resistance in San Francisco, 2000–2002 [abstract 120]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S134.
Chaix ML, Descamps D, Mouajjah S, et al.: French National Sentinel Survey of antiretroviral resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001–2002 [abstract 123]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico; 2003:S137.
Turner D, Brenner BG, Routy JP, et al.: Decreased rates of transmission of drug-resistant HIV-1 strains containing the M184V mutation in reverse transcriptase [abstract 129]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S143.
Deeks SG, Wrin T, Liegler T, et al.: Virologic and immunologic consequences of discontinuing combination antiretroviraldrug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472–480.
Little SJ, Dawson K, Hellman NS, et al.: Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy [abstract 115]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S129.
Hirsch MS, Brun-Vezinet F, Clotet B, et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003, 37:113–128. These are the most recent guidelines for the use of HIV resistance testing in all circumstances.
Markowitz M, Vesanen M, Tenner-Racz K, et al.: The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999, 179:525–537.
Smith DE, Kaufman GR, Kahn JO, et al.: Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. AIDS Res Hum Retroviruses 2003, 19:189–199.
Hecht RA, Hare CB, McGrath MS, et al.: Interleukin-2 (IL-2) in conjunction with HAART in early HIV infection increases naïve and memory CD4 cells and lowers activation markers [abstract 649]. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections 2003. Boston: Foundation for Retrovirology and Human Health, NIAID, and CDC; 2003.
Rizzardi GP, Harari A, Capiluppi B, et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002, 109:681–688.
Markowitz M, Jin X, Hurley A, et al.: Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2003, 186:634–643.
Wasserman S: HIV/AIDS: partner notification programs. Issue brief. Health Policy Tracking Service; 2000.
Osborn JE. AIDS: politics and science. N Engl J Med 1988, 318:444–447.
Golden MR: HIV partner notification: a neglected prevention intervention. Sex Transm Dis 2002, 29:472–475. This is a good review of the history of and current issues surrounding partner notification.
Golden MR, Hogben M, Handsfield HH, et al.: Partner notification for HIV and STD in the United States: love coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis 2003, 30:490–496.
Kissinger PJ, Niccolai LM, Magnus M, et al.: Partner notification for HIV and syphilis: effects on sexual behaviors and relationship stability. Sex Transm Dis 2003, 30:89–90.
Hoxworth T, Spencer NE, Peterman TA, et al.: Changes in partnerships and HIV risk behavior after partner notification. Sex Transm Dis 2003, 30:83–88.
Landis SE, Schoenbach VJ, Weber DJ, et al.: Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. N Engl J Med 1992, 326:101–106.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hare, C.B., Kahn, J.O. Primary HIV infection. Curr Infect Dis Rep 6, 65–71 (2004). https://doi.org/10.1007/s11908-004-0026-1
Issue Date:
DOI: https://doi.org/10.1007/s11908-004-0026-1